Denali Therapeutics (NASDAQ:DNLI) Stock Price Target Raised at Wedbush

Denali Therapeutics (NASDAQ:DNLI) had its price objective lifted by Wedbush from $23.00 to $24.00 in a research report released on Wednesday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts also recently commented on the company. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, October 24th. UBS Group increased their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Robert W. Baird set a $34.00 price target on shares of Denali Therapeutics in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, JPMorgan Chase & Co. started coverage on shares of Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 price target on the stock. Thirteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $36.15.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $20.96 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.32 and a current ratio of 8.37. Denali Therapeutics has a 52 week low of $13.75 and a 52 week high of $27.30. The stock has a market capitalization of $3.35 billion, a P/E ratio of -12.12 and a beta of 1.08. The stock has a fifty day moving average of $20.35 and a 200-day moving average of $21.25.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.64. The business had revenue of $17.78 million for the quarter, compared to the consensus estimate of $12.67 million. During the same quarter in the prior year, the company earned ($0.74) earnings per share. On average, sell-side analysts expect that Denali Therapeutics will post -2.70 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total transaction of $71,624.99. Following the sale, the insider owned 281,763 shares of the company’s stock, valued at $7,063,798.41. This trade represents a 1.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNLI. BlackRock Inc. acquired a new position in Denali Therapeutics in the 2nd quarter worth about $360,759,000. Dimensional Fund Advisors LP boosted its stake in shares of Denali Therapeutics by 13.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company’s stock valued at $51,687,000 after purchasing an additional 317,872 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Denali Therapeutics by 3,490.9% during the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock valued at $35,932,000 after purchasing an additional 1,819,339 shares in the last quarter. Defilade Capital Management L.P. boosted its stake in shares of Denali Therapeutics by 107.1% during the first quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company’s stock valued at $26,111,000 after purchasing an additional 703,256 shares in the last quarter. Finally, Bank of America Corp DE acquired a new stake in shares of Denali Therapeutics during the second quarter valued at about $31,660,000. Institutional investors own 92.92% of the company’s stock.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: AVLAYAH sales and Q4 outlook: Net product revenue reached $17.8 million in the second full commercial quarter. Denali expects Q4 2026 product revenue of $30 million to $32 million, signaling substantial near-term growth. Denali Q3 2026 financial results and business highlights
• Positive Sentiment: Revenue beat estimates: Q3 revenue of $17.78 million topped analyst expectations of $12.67 million. The company also reported a $70.1 million net income for the quarter. Denali Therapeutics soars on earnings beat
• Positive Sentiment: Analyst targets raised: Morgan Stanley lifted its target to $42 and maintained Overweight; Wedbush raised its target to $24 and maintained Outperform. BTIG reaffirmed Buy with a $39 target. The higher targets reflect analyst optimism, though they are not guarantees of future performance. Read More., Read More., Read More.
• Positive Sentiment: Pipeline and balance sheet: Denali said a 2027 BLA filing for zafinofusp is on track and expects data from five TransportVehicle programs in 2027. Cash, equivalents and marketable securities totaled $1.0 billion. Denali Q3 2026 financial results and business highlights
• Neutral Sentiment: Earnings quality context: Q3 net income included a one-time $194 million gain from selling a Priority Review Voucher, so the reported profit is not solely reflective of recurring operations. Denali Q3 2026 financial results and business highlights

Denali Therapeutics Company Profile

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.